NCT00031993View on ClinicalTrials.gov

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

November 30, 2005

Conditions
Cervical Squamous Cell CarcinomaRecurrent Cervical Cancer
Interventions
DRUG

erlotinib hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00031993 - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | Biotech Hunter | Biotech Hunter